Side-by-side comparison
AbbVie vs Gilead Sciences
As of Sep 25, 2026, P/S is 7.3x for AbbVie vs 6.1x for Gilead Sciences; revenue growth is 10.4% for AbbVie vs 5.5% for Gilead Sciences; operating margin is 26.2% for AbbVie vs -8.2% for Gilead Sciences; net margin is 9.8% for AbbVie vs -10.6% for Gilead Sciences.
Key metrics
| Metric | ABBV | GILD |
|---|---|---|
| Price | $264.34 | $150.93 |
| Market cap | $467.12B | $187.15B |
| P/E | 74.7x (#1) | — |
| P/S | 7.3x (#2) | 6.1x (#1) |
| Revenue growth | 10.4% (#1) | 5.5% (#2) |
| Operating margin | 26.2% (#1) | -8.2% (#2) |
| Net margin | 9.8% (#1) | -10.6% (#2) |
| Debt / equity | — | 2.01 (#1) |
| 1-year return | +19.8% (#2) | +34.6% (#1) |
| Research score | 55/100 (#1) | 42/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General